INNOVATION ARTICLES

INNOVATION VIDEOS

Explore how human-relevant liver models can improve DILI risk assessment and support stronger development decisions while advancing toward regulatory qualification and scaling into automated studies.

Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.

Boost scalability in bioprocessing with automated filtration solutions designed for commercial-scale operations. Achieve reliable performance, low working volumes, and large filtration areas.

Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.

INNOVATION ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS

INNOVATION SOLUTIONS

  • Overcome protein expression bottlenecks with a scalable insect-based platform that delivers faster development, predictable scale-up, and consistent manufacturing.

  • Produce recombinant proteins at scale with stable expression, flexible batch sizes, and streamlined manufacturing.

  • Capturing dynamic conformational states is key to target druggability. Advanced EPR spectroscopy delivers nanometer-resolution measurements for complex structural biology.

  • Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.

  • Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.

  • Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.

  • Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.

  • Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.

  • Our collaborative approach, proven track record, and deep technical expertise enable us to efficiently advance promising candidates, reduce development risk, and help transform innovative ideas into successful therapeutic realities.

  • Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.

  • Make the most of your molecule with integrated antibody discovery, engineering, and production capabilities designed to accelerate lead identification and optimization.

  • The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.

  • Our Biologics services provide comprehensive Molecular Biology services at facilities in California and Massachusetts, offering a variety of services.

  • Curia has decades of experience in recombinant protein production.